Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp, or Approximately 250 cm2 on the Chest: A Phase III, Randomized, Controlled Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.2.supp.46 ◽

2018 ◽

Vol 2 ◽

pp. S46 ◽

Cited By ~ 1

Author(s):

C William Hanke ◽

Lorne Albrecht ◽

Laerke K Kyhl ◽

Thomas Larrson ◽

Marie L Oesterdal ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Actinic Keratosis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Ingenol Mebutate ◽

Randomized Controlled ◽

Full Face

Abstract not available. Disclosures: Study supported by LEO Pharma. Copyright SKIN 2018

Download Full-text

Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm2 on the chest: A phase 3 randomized controlled trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.07.083 ◽

2020 ◽

Vol 82 (3) ◽

pp. 642-650 ◽

Cited By ~ 1

Author(s):

C. William Hanke ◽

Lorne Albrecht ◽

Torsten Skov ◽

Thomas Larsson ◽

Marie Louise Østerdal ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Actinic Keratosis ◽

Controlled Trial ◽

Efficacy And Safety ◽

Ingenol Mebutate ◽

Phase 3 ◽

Randomized Controlled ◽

Full Face

Download Full-text

A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial

Clinical Therapeutics ◽

10.1016/j.clinthera.2017.12.018 ◽

2018 ◽

Vol 40 (2) ◽

pp. 226-241.e4 ◽

Cited By ~ 11

Author(s):

Soon Jun Hong ◽

Han Saem Jeong ◽

Jeong Cheon Ahn ◽

Dong-Hun Cha ◽

Kyung Heon Won ◽

...

Keyword(s):

Clinical Trial ◽

Randomized Controlled Trial ◽

Combination Therapy ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Active Comparator ◽

Randomized Controlled

Download Full-text

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Efficacy and safety of rebel reliever ® brace in patients with knee osteoarthritis – A phase III randomized controlled trial

Osteoarthritis and Cartilage ◽

10.1016/j.joca.2017.02.702 ◽

2017 ◽

Vol 25 ◽

pp. S407

Author(s):

P. Thoumie ◽

B. Avouac ◽

M. Marty ◽

A. Pallez

Keyword(s):

Randomized Controlled Trial ◽

Knee Osteoarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Randomized Controlled

Download Full-text

Efficacy and Safety of Riluzole in Acute Spinal Cord Injury (SCI): Rationale and Design of Aospine Phase III Multicenter Double Blinded Randomized Controlled Trial (Riscis)

The Spine Journal ◽

10.1016/j.spinee.2016.07.518 ◽

2016 ◽

Vol 16 (10) ◽

pp. S377

Author(s):

Michael G. Fehlings ◽

Branko Kopjar ◽

Robert G. Grossman

Keyword(s):

Spinal Cord ◽

Spinal Cord Injury ◽

Randomized Controlled Trial ◽

Controlled Trial ◽

Acute Spinal Cord Injury ◽

Phase Iii ◽

Efficacy And Safety ◽

Randomized Controlled ◽

Cord Injury ◽

Double Blinded

Download Full-text

Single-blind, randomized controlled trial to evaluate the efficacy and safety of photodynamic therapy using aminolevulinic acid versus 5-fluorouracil in the management of actinic keratosis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2003.10.443 ◽

2004 ◽

Vol 50 (3) ◽

pp. P129 ◽

Cited By ~ 1

Author(s):

Aditya K Gupta

Keyword(s):

Randomized Controlled Trial ◽

Photodynamic Therapy ◽

Actinic Keratosis ◽

Aminolevulinic Acid ◽

Controlled Trial ◽

Efficacy And Safety ◽

Randomized Controlled ◽

Acid Versus ◽

Single Blind

Download Full-text

Response to ‘Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp’: reply from the authors

British Journal of Dermatology ◽

10.1111/bjd.16225 ◽

2018 ◽

Vol 178 (3) ◽

pp. 813-814 ◽

Cited By ~ 1

Author(s):

E. Stockfleth ◽

C.A. Harwood ◽

C. Serra-Guillén ◽

T. Larsson ◽

M.L. Østerdal ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Actinic Keratosis ◽

Controlled Trial ◽

Diclofenac Sodium ◽

Ingenol Mebutate ◽

Randomized Controlled ◽

The Face ◽

Phase Iv

Download Full-text

Response to ‘Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp’

British Journal of Dermatology ◽

10.1111/bjd.16216 ◽

2018 ◽

Vol 178 (3) ◽

pp. 812-813

Author(s):

J. Malvehy ◽

S. Puig

Keyword(s):

Randomized Controlled Trial ◽

Actinic Keratosis ◽

Controlled Trial ◽

Diclofenac Sodium ◽

Ingenol Mebutate ◽

Randomized Controlled ◽

The Face ◽

Phase Iv

Download Full-text

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2015.03.049 ◽

2015 ◽

Vol 73 (1) ◽

pp. 37-49 ◽

Cited By ~ 273

Author(s):

Kim Papp ◽

Kristian Reich ◽

Craig L. Leonardi ◽

Leon Kircik ◽

Sergio Chimenti ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Pde4 Inhibitor ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725781037.793521633 ◽

2016 ◽

Author(s):

Gil Yosipovitch ◽

Leigh Nattkemper

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text